Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial

Philipp le Coutre, Joachim R Göthert, Susanne Saussele, Uwe Pelzer, Lars Bullinger, Ahmet Elmaagacli, Christian Jehn, Frank Stegelmann, Andreas Hochhaus, Thomas Ernst, Andreas Burchert

Blood (2022) 140 (Supplement 1): 12202–12203.

https://doi.org/10.1182/blood-2022-162281

Published: 2022

Journal Articles

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Blood (2022) 140 (Supplement 1): 947–949.

https://doi.org/10.1182/blood-2022-159412

Published: 2022

Journal Articles

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Katja Sockel, Sandra Frank, Annika Neu, Markus Ditschkowski, Inken Hilgendorf, Mareen Goeckenjan, Friedrich Stoelzel, Jan Moritz Middeke, Nicolaus Kröger, Francis A. Ayuk, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Barbara Holler, Daniel Wolff, Thomas Luft, Wolf Roesler, Kerstin Schäfer-Eckart, Sabine Dressler, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christoph Wittke, Friederike Wortmann, Helga Neidlinger, Martin Bornhaeuser, Johannes Schetelig, on Behalf of the German Cooperative Transplant Study Group

Blood (2022) 140 (Supplement 1): 10563–10565.

https://doi.org/10.1182/blood-2022-162673

Published: 2022

Journal Articles

ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Thomas Ernst, Lioba Schönfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schäfer, Thomas Schenk, Christian Fabisch, Tim H. Brümmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 807–808.

https://doi.org/10.1182/blood-2022-165041

Published: 2022

Journal Articles

Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex - Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group

Susanne Isfort, Dominik Wolf, Lino L. Teichmann, Martina Crysandt, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Alexander Kiani, Joachim R Göthert, Thomas Illmer, Philippe Schafhausen, Mareille Warnken-Uhlich, Uta Wolber, Denise Kohn, Kirsi Manz, Markus Pfirrmann, Tim H.H. Brummendorf

Blood (2022) 140 (Supplement 1): 12194–12196.

https://doi.org/10.1182/blood-2022-164607

Published: 2022

Journal Articles

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Blood (2022) 140 (Supplement 1): 1501–1503.

https://doi.org/10.1182/blood-2022-169324

Published: 2022

Journal Articles

Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

Blood (2022) 140 (Supplement 1): 6262–6264.

https://doi.org/10.1182/blood-2022-164702

Published: 2022

Journal Articles

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Blood (2022) 139 (1): 87–103.

https://doi.org/10.1182/blood.2020009680

Published: 2022

Includes: Supplemental data

Journal Articles

Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response

Susanne Isfort, Dominik Wolf, Lino L. Teichmann, Martina Crysandt, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Alexander Kiani, Joachim R. Göthert, Thomas Illmer, Philippe Schafhausen, Mareille Warnken-Uhlich, Uta Wolber, Denise Kohn, Kirsi Manz, Markus Pfirrmann, Tim H Brümmendorf

Blood (2021) 138 (Supplement 1): 3608.

https://doi.org/10.1182/blood-2021-151240

Published: 2021

Journal Articles

Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience

Blood (2021) 138 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2021-145917

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Blood (2021) 138 (Supplement 1): 173.

https://doi.org/10.1182/blood-2021-145167

Published: 2021

Journal Articles

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Jani Huuhtanen, Jason Theodoropoulos, BSc, Rebecca Warfvinge, MSc, Andreas Burchert, MD, Tiina Kasanen, Jay Klievink, MSc, Shady Adnan Awad, MD, Olli Dufva, MD, Mette Ilander, PhD, Taina Jaatinen, Ulla Olsson-Strömberg, MD PhD, Henrik Hjorth-Hansen, MD, Göran Karlsson, PhD, Harri Lähdesmäki, PhD, Anna Kreutzman, PhD, Satu Mustjoki, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139134

Published: 2020

Journal Articles

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1647.

https://doi.org/10.1182/blood-2019-129710

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Blood (2019) 134 (Supplement_1): 495.

https://doi.org/10.1182/blood-2019-130043

Published: 2019

Journal Articles

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Blood (2019) 134 (Supplement_1): 666.

https://doi.org/10.1182/blood-2019-127127

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Blood (2018) 132 (Supplement 1): 460.

https://doi.org/10.1182/blood-2018-99-112119

Published: 2018

Journal Articles

Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial

Jürgen Finke, MD, Claudia Schmoor, Matthias Stelljes, MD, Andreas Burchert, MD, Peter Dreger, Eva-Maria Wagner, MD, Martin Bornhäuser, Kristina Sohlbach, MD, Natalie Schub, MD, Christian Reicherts, Guido Kobbe, Bertram Glass, Hartmut Bertz, MD, Olga Grishina

Blood (2018) 132 (Supplement 1): 210.

https://doi.org/10.1182/blood-2018-99-118999

Published: 2018

Journal Articles

Pathological Hepatic Contrast-Enhanced Ultrasound (CEUS) Pattern in Patients Undergoing Allogeneic Stem Cell Transplantation (allo-SCT)

Corinna Trenker, MD, Andreas Burchert, MD, Christian Sebastian Michel, MD, Caren Schuhmacher, Student, Jonas A. Schäfer, MD, Marius Dohse, MD, Andreas Neubauer, MD, Kristina Sohlbach, MD, Christian Görg, MD

Blood (2018) 132 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2018-99-110479

Published: 2018

Journal Articles

Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial

Blood (2018) 132 (Supplement 1): 661.

https://doi.org/10.1182/blood-2018-99-112614

Published: 2018

Journal Articles

Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2018-99-118128

Published: 2018

NARROW

Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex - Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response

Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial

Pathological Hepatic Contrast-Enhanced Ultrasound (CEUS) Pattern in Patients Undergoing Allogeneic Stem Cell Transplantation (allo-SCT)

Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial

Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only